Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-infiltrating lymphocytes stimulated by dendritic cells
- Development stage
- Unknown
- Lead developer
- Gansu Provincial People's Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous tumor-infiltrating lymphocytes stimulated by dendritic cells (DC-TIL) is an autologous adoptive cell therapy being developed for the treatment of malignant solid tumors. The therapy involves the isolation of tumor-infiltrating lymphocytes (TILs) from a patient's tumor tissue, which are then co-cultured and stimulated ex vivo with autologous dendritic cells (DCs). Dendritic cells, acting as potent antigen-presenting cells, are often pulsed with tumor-associated antigens to enhance the activation and expansion of tumor-specific T cell populations within the TIL product. This process aims to overcome the immunosuppressive tumor microenvironment and generate a more robust anti-tumor immune response upon re-infusion into the patient. The approach is currently being evaluated in Phase I clinical trials sponsored by Gansu Provincial Hospital.
- Other names
- autologous DC-TILdendritic cell-stimulated tumor-infiltrating lymphocytes
02
Targets
PD-1 (Programmed cell death protein 1)Neoantigen-specific T-cell receptor
Beyond the preview
Go deeper on autologous tumor-infiltrating lymphocytes stimulated by dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-infiltrating lymphocytes stimulated by dendritic cells.